Cder ectd regulated product submission task order
Ended Awarded Last action
- Contract number
- 75F40123F19289
- Awardee
-
Brillient Corporation UEI MMAVC7UGLJ78
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $122,611
Award facts
- Contract value 100% obligated
- $122,611.14 Current and potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541611 Administrative Management and General Management Consulting Services
- PSC
- R499 Support- Professional: Other
- Set-aside
- Competitive 8(a)
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Time and Materials
- Place of performance
- Reston, VA 20190, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$7,610 | |
| Original award | $130,221 |
About this award
The U.S. Food and Drug Administration (FDA) awarded a $122,611.14 task order to Brillient Corporation, a minority-owned digital transformation company, under a Professional and Technical Services Blanket Purchase Agreement. The award, made on July 12, 2023, is designated as a Competitive 8(a) set-aside and is scheduled for completion by May 25, 2026. Work will be performed in Reston, Virginia, with pricing structured on a time and materials basis. The task order supports the FDA's Center for Drug Evaluation and Research (CDER) in processing electronically Common Technical Document (eCTD) regulated product submissions, which are critical submissions for pharmaceutical and biologic product approvals.
This task order is issued under a General Services Administration Multiple Award Schedule contract vehicle, allowing the FDA to leverage pre-competed pricing and terms for professional services. Brillient Corporation brings substantial federal contracting experience, having delivered similar services to the FDA and other health and human services agencies, including technical writing, program management, and administrative support. The contractor's minority-owned business status aligns with the 8(a) set-aside designation, supporting small business participation in federal procurement while ensuring the FDA receives specialized technical expertise to support its regulatory operations.
Quick answers
Who was awarded contract 75F40123F19289?
75F40123F19289 was awarded to Brillient Corporation by Food and Drug Administration (Department of Health and Human Services) on July 12, 2023.
How much is contract 75F40123F19289 worth?
The government has obligated $122,611 on 75F40123F19289.
Is contract 75F40123F19289 an order under another contract?
Yes. 75F40123F19289 is a BPA call under GS00F012BA-HHSF223201810005B, a blanket purchase agreement, on Multiple Award Schedule (MAS).
Was contract 75F40123F19289 competed?
The extent of competition for 75F40123F19289 was full and open competition. It was set aside: Competitive 8(a).
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award